After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.